课题基金 / 基金详情

IMMUNOASSAYS FOR DETECTION OF MYCOBACTERIUM TUBERCULOSIS

IMMUNOASSAYS FOR DETECTION OF MYCOBACTERIUM TUBERCULOSIS
检测结核分枝杆菌的免疫测定法
批准号:
7959047
负责人:
Paul Luciw
金额:
$7.33万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-05-01 至 2010-04-30

项目摘要

项目成果

Paul Luciw的其他基金

相似基金

相关文献

中文摘要
翻译
该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者(PI)可能从另一个NIH来源获得主要资金, 因此可以在其他CRISP条目中表示。列出的机构是 中心,不一定是研究者的机构。 目前检测结核分枝杆菌(M.tb.)非人灵长类动物感染具有显著的局限性。 因此,本项目旨在开发新型的多重免疫测定方法,以测量抗体和细胞介导的对结核分枝杆菌的免疫应答。在恒河猴中。 该项目建立在(1)分枝杆菌基因组学,蛋白质组学和免疫学的知识和(2)传染病的新型诊断仪器的最新进展。 本项目开发的新型多重免疫测定方法对于建立和维持非人灵长类动物的无特异性病原体(SPF)菌落至关重要,以便最佳地用于生物医学研究,包括使用猕猴进行艾滋病研究。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Current methods to detect Mycobacterium tuberculosis (M.tb.) infection of non-human primates have significant limitations. Accordingly, this project aims to develop novel multiplex immunoassay methods to measure both antibody and cell-mediated immune responses to M.tb. in rhesus macaques. This project builds on recent advances in (1) knowledge of mycobacteria genomics, proteomics, and immunology and (2) novel diagnostic instrumentation for infectious disease. The novel multiplex immunoassay methods developed in this project will be essential for establishing and maintaining specific-pathogen-free (SPF) colonies of non-human primates for optimal use in biomedical research, including the use of macaques for AIDS research.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Nonhuman Primate Model for Eradication Therapy
Animal Resources and Laboratory Services
  • 批准号:
    8260271
  • 项目类别:
  • 资助金额:
    $7.05万
  • 财政年份:
    2011
  • 负责人:
    Paul Luciw
  • 依托单位:
IMMUNOASSAYS FOR DETECTION OF MYCOBACTERIUM TUBERCULOSIS
NONHUMAN PRIMATE MODEL FOR TB VACCINES
海外基金